Abstract:Abstract Background Pharmacological modulation of cell fate decisions and developmental gene regulatory networks holds promise for the treatment of heart failure. Compounds that target tissue-specific transcription factors could overcome non-specific effects of small molecules and lead to the regeneration of heart muscle following myocardial infarction. Due to cellular heterogeneity in the heart, the activation of gene programs representing specific atrial and ventricular cardiomyocyte subtypes would be highly desirable. Chemical compounds that modulate atrial and ventricular cell fate could be used to improve subtype-specific differentiation of endogenous or exogenously delivered progenitor cells in order to promote cardiac regeneration. Methods Transcription factor GATA4-targeted compounds that have previously shown in vivo efficacy in cardiac injury models were tested for stage-specific activation of atrial and ventricular reporter genes in differentiating pluripotent stem cells using a dual reporter assay. Chemically induced gene expression changes were characterized by qRT-PCR, global run-on sequencing (GRO-seq) and immunoblotting, and the network of cooperative proteins of GATA4 and NKX2-5 were further explored by the examination of the GATA4 and NKX2-5 interactome by BioID. Reporter gene assays were conducted to examine combinatorial effects of GATA-targeted compounds and bromodomain and extraterminal domain (BET) inhibition on chamber-specific gene expression. Results GATA4-targeted compounds 3i-1000 and 3i-1103 were identified as differential modulators of atrial and ventricular gene expression. More detailed structure-function analysis revealed a distinct subclass of GATA4/NKX2-5 inhibitory compounds with an acetyl lysine-like domain that contributed to ventricular cells (%Myl2-eGFP+). Additionally, BioID analysis indicated broad interaction between GATA4 and BET family of proteins, such as BRD4. This indicated the involvement of epigenetic modulators in the regulation of GATA-dependent transcription. In this line, reporter gene assays with combinatorial treatment of 3i-1000 and the BET bromodomain inhibitor (+)-JQ1 demonstrated the cooperative role of GATA4 and BRD4 in the modulation of chamber-specific cardiac gene expression. Conclusions Collectively, these results indicate the potential for therapeutic alteration of cell fate decisions and pathological gene regulatory networks by GATA4-targeted compounds modulating chamber-specific transcriptional programs in multipotent cardiac progenitor cells and cardiomyocytes. The compound scaffolds described within this study could be used to develop regenerative strategies for myocardial regeneration.

Abstract 11415: Enhancing Direct Cardiac Reprogramming Efficiency Using Small Molecules

Chemical Enhancement of in Vitro and in Vivo Direct Cardiac Reprogramming.

Robust Small Molecule-Aided Cardiac Reprogramming Systems Selective to Cardiac Fibroblasts

Cardiac regeneration by direct reprogramming in this decade and beyond

Small Molecules Enable Cardiac Reprogramming of Mouse Fibroblasts with a Single Factor, Oct4.

Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction

Abstract 15007: Chemical Enhancement of Direct Cardiac Reprogramming in Vitro and in Vivo

Optimization of direct fibroblast reprogramming to cardiomyocytes using calcium activity as a functional measure of success

Regulation of cardiac fibroblasts reprogramming into cardiomyocyte‐like cells with a cocktail of small molecule compounds

Improved Cardiac Function in Postischemic Rats Using an Optimized Cardiac Reprogramming Cocktail Delivered in a Single Novel Adeno-Associated Virus

Direct Reprogramming of Human Fibroblasts Toward the Cardiomyocyte Lineage

Sall4 and Myocd Empower Direct Cardiac Reprogramming From Adult Cardiac Fibroblasts After Injury

Improving Cardiac Reprogramming for Heart Regeneration in Translational Medicine

Direct Cardiac Reprogramming in the Age of Computational Biology

Recent advances and future prospects in direct cardiac reprogramming

Direct Reprogramming of Human Fibroblasts Toward a Cardiomyocyte-Like State.

Abstract 19996: Cardiac Mesenchymal Stem Cells with High Endogenous Gata4 Promoter Activity Have Superior Capacity to Elicit Cardiac Repair

GATA-targeted compounds modulate cardiac subtype cell differentiation in dual reporter stem cell line

Production of Cardiomyocytes by microRNA-Mediated Reprogramming in Optimized Reprogramming Media

Direct in Vivo Reprogramming with Non-Viral Sequential Targeting Nanoparticles Promotes Cardiac Regeneration.

Direct reprogramming of mouse fibroblasts into cardiomyocytes with chemical cocktails